Amcinonide

Compare Amcinonide  to:
Compare
Compare

Generic Name for Amcinonide

Amcinonide 0.1%; crm; oint; lotion.

Legal Classification:

Rx

Manufacturer of Amcinonide

Various generic manufacturers

Indications for Amcinonide

Corticosteroid-responsive dermatoses.

Adults and Children:

Apply thin film 2–3 times daily (crm, oint) or 2 applications daily (lotion).

Contraindications for Amcinonide

Do not use superpotent forms on face, groin, or axillae. Exclude viral disease (eg, chickenpox, measles).

Warnings/Precautions for Amcinonide

Treat infection if present; discontinue if infection persists or worsens. Do not use near eyes, or on diaper dermatitis or pre-existing skin atrophy. Do not use fluorinated steroids longer than 1 week on the face. Avoid abrupt cessation in chronic use. Systemic absorption increased by broken or inflamed skin, prolonged use, application to large surface area, or use of occlusive dressings. Occlude only if necessary; do not occlude higher potency products. Monitor adrenal function in children if a high potency product or occlusion is used, and in adults if more than 50g weekly of a high potency product is used. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, hyperglycemia, glucosuria, or irritation occurs. Use lowest effective dose and potency (esp. in children). Use caution if applying to face or body folds. Do not use continuously or for prophylaxis. Foams are flammable. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.

Adverse Reactions for Amcinonide

Burning, stinging, pruritus, erythema, skin atrophy, striae, miliaria, secondary infections, hypopigmentation, folliculitis, hypertrichosis, acneiform eruptions, dermal cracking and fissuring, telangiectasia, contact dermatitis, other local effects, immunosuppression, masks infections, HPA axis suppression (esp. in children).

How is Amcinonide supplied?

Contact supplier.

Related Disease:

Dermatitis~topical steroids

Related Resources

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

Nozzle redesigned for Clobex Spray for plaque psoriasis

April 13, 2010

Galderma announced the availability of a new nozzle for Clobex (clobetasol propionate) Spray, a topical steroid indicated for the treatment of moderate to severe plaque psoriasis in adults ≥18 years of age.

Pediaderm HC Complete Kit available for atopic dermatitis

March 09, 2010

Arbor Pharmaceuticals announced the launch of Pediaderm HC Complete Kit which contains Pediaderm HC (hydrocortisone lotion 2%) and nonsteroidal Pediaderm Protective Emollient with Triple Synergy Technology.

Restylane-L and Perlane-L dermal fillers approved

February 03, 2010

The FDA has approved Medicis' hyaluronic acid with lidocaine dermal fillers, Restylane-L and Perlane-L.

Juvéderm XC dermal filler approved

February 02, 2010

The FDA has approved Juvéderm XC (hyaluronic acid and lidocaine [preservative-free] injectable gel, from Allergan) dermal filler for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (eg, nasolabial folds).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions